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In this Chapter, we are mainly concerned with mathematical modelling (using differential 
equations) of  controlled continuous  subcutaneous infusion of insulin in Type 1 diabetes 
using pumps. It occurs mainly in children where controlling levels of sugar is entirely 
dependent on external infusion of insulin. Type I diabetes is a result of loss of beta-cell 
functions in the body due to an autoimmune reaction There is vast literature concerning 
continuous infusion of insulin where feedback is intermittent and the dosage is adhoc. Other 
ways of combating Type I diabetes include transplantation of insulin producing tissues or 
introducing artificial beta cells. We mathematically model the sugar concentration in the 
body and use it to dovetail a previously medically prescribed sugar concentration curve. 
The modelling, for the first time, aids the continuous infusion of insulin based upon 
individuals requirements in terms of the curve of  decay of sugar concentration in a 
prescribed time. For each individual, depending on many personal factors  like obesity, age, 
kidney functions, etc., a prescription is made of the desirable curve of sugar concentration 
from its highest level to the desired lowest level in a given period of time. This fine tunes the 
delivery of insulin as it takes away much guesswork of amounts of insulin given 
intermittently or continuously. Devices attached to continuous monitoring device will infuse 
insulin continuously and as per prescribed curve of reduction of sugar concentration. Thus, 
the pumps delivery takes into consideration the time profile of the insulin release, with the 
release stopping after the prescribed values are attained. The amount released in a dual 
wave shaped insulin bolus combining [8] both the usual normal and square wave methods. 
The therapy described will be the forerunner of intense clinical research work.Mathematical 
models with numerical simulations and analysis based on experimental data can be more 
effective in terms of costs and an extraordinary amount of time dealing with diverse 
physiological situations. This is particularly so in view of the complexities of the functions in 
the human body and incomplete existing knowledge. 
This chapter provides an overview of mathematical modelling of type 1 diabetes, with 
particular focus on pump therapy as a management strategy for continuous subcutaneous 
insulin infusion. Previous models describing the mechanism of glucose metabolism have 
mostly focused on type 2 diabetes, most notably the classical minimal model for explaining 
the profile of glucose concentration over time.[4,5] Here we summarize the conclusions of 
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these studies for management of diabetes, and attempt to lay out a framework for further 
development of these models to include pump therapy. These models are often formulated 
as a system of differential equations that describes the profile of insulin release and the 
dynamics of glucose concentration over specified period of time. In addition to providing 
background on existing modelling frameworks, the practical implications of their outputs 
are discussed.  
The main goals are (a) formulation of the model using the pump mechanism (b) defining the 
parameters (c) profiling the insulin release (d) simulating using estimated parameter values 
and (e) modelling extensions to include obesity as it had been well established that obesity 
promotes insulin resistance through the inappropriate inactivation of a process called 
gluconeogenesis, where the liver creates glucose for fuel. The model consists of blood 
glucose concentration, remote insulin action and amount of insulin. The model predictions 
include insulin secreted, if any, in pancreas, role of other organs, tissue uptake etc. This 
chapter closes with future direction in mathematical modelling of type 1 diabetes for 
optimal usage of external insulin and measuring insulin dependency with an insight into 
the role of obesity in developing diabetes. 
2. Diabetes 
2.1 What is diabetes? 
Diabetes is a global problem with devastating human, social and economic impact. Diabetes 
is a growing epidemic threatening to overwhelm global healthcare services, wipe out some 
indigenous populations and undermine economies worldwide, especially in developing 
countries. Today more than 250 million people worldwide are living with diabetes and by 
2025, this total is expected to increase to over 380 million people. Approximately 24 million 
people are diabetics in United States which is about 8 percent of the total population. The 
number of people with diabetes is increasing due to population growth, aging, urbanization, 
and increasing prevalence of obesity and physical inactivity. Diabetes is a highly prevalent 
disease in India where more than 35 million people suffer from diabetes. Alarmingly, as 
much as 13 million cases remains undiagnosed which leads to long term complications. The 
prevalence of diabetes is greater amongst the urban South Asian population (12-15%) 
compared to urban population in the West (6%).[9] That is why Diabetes has been one of the 
most important subjects for biomedical research for many years. 
Diabetes Mellitus, commonly referred to as Diabetes, means sweet urine. Consistently 
elevated levels of blood glucose lead to spillage to glucose into urine, hence the term sweet 
urine. When the blood sugar level consistently runs too high in our blood stream, the 
condition is named as Diabetes. In patients with Diabetes Mellitus, the absence or 
insufficient production of insulin by the liver causes hyperglycemia. Diabetes Mellitus is a 
syndrome characterized by chronic hyperglycemia resulting from absence or relative 
impairment in insulin secretion and/or insulin action. It can also be referred to as a 
condition characterized by the disturbances of carbohydrate, protein and fat metabolism, the 
way our bodies use digested food for growth and energy. The chronic hyperglycemia of 
diabetes is associated with long term damage, dysfunction and failure of various organs, 
especially the eyes, kidneys, nerves, heart and blood vessels.[7] Diabetes is the most 
common endocrine disorder. It is a chronic medical condition meaning it can last a lifetime 
which can be controlled but can not be cured completely. 
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Human body functions best at a certain level of sugar in the blood stream. Blood sugar 
levels are tightly controlled by insulin, the principal hormone that makes it possible for 
many cells (primarily muscle and fat cells) to use glucose from the blood. It is manufactured 
by the beta cells of the pancreatic islets of Langerhans, a small section of the pancreas. 
Secretion of insulin primarily occurs in response to increased concentration of glucose in the 
blood. Insulin helps the glucose from food get into the body cells. If body does not make 
enough insulin or if the insulin does not work the way it should, glucose can not get into the 
cells. It stays in the blood instead and blood glucose level gets too high causing to have 
Diabetes. Deficiency of insulin or its action plays a central role in all forms of diabetes. There 
are three major forms of diabetes:[18] 
2.1.1 Type 1 diabetes 
Type 1 diabetes is one of the most challenging medical disorder because of the demands it 
imposes on day-to-day life. It was formerly known as insulin dependent diabetes mellitus 
(IDDM) or juvenile onset diabetes mellitus.  
In this type of diabetes, the pancreas undergoes an autoimmune attack by the body itself 
and is rendered incapable of making insulin. It is an autoimmune disorder, in which body’s 
own immune system attacks the beta cells in the islets of Langerhans of the pancreas 
destroying them or damaging them sufficiently to reduce insulin production. The pancreas 
then produces little or no insulin. At present, scientists do not know exactly what causes the 
body's immune system to attack the beta cells, but it is believed that autoimmune, genetic, 
and environmental factors, possibly viruses, are involved. It develops most often in children 
and young adults, but can appear at any age.Type 1 diabetes, which predominately affects 
youth, is rising alarmingly worldwide, at a rate of 3% per year. Some 70,000 children 
worldwide are expected to develop type 1 diabetes annually. If not diagnosed and treated 
with insulin, a person with type 1 diabetes can lapse into a life-threatening diabetic coma, 
also known as diabetic ketoacidosis. 
2.1.2 Type 2 diabetes 
Type 2 diabetes, formerly called adult-onset diabetes or non-insulin- dependent diabetes 
mellitus (NIDDM), is the most common form of diabetes. Type 2 diabetes is responsible for 
90 -95% of diabetes cases and is increasing at alarming rates globally as a result of increased 
urbanization, high rates of obesity, sedentary lifestyles and stress. Type 2 diabetes is 
increasingly being diagnosed in children and adolescents though it can occur at any age. 
Millions of people don’t even know they have it because it can arise with minimal outward 
signs or symptoms. It is diagnosed with insulin resistance in which the pancreas is 
producing enough insulin but for unknown reasons, the body can not use the insulin 
effectively. This leads to a situation similar to type 1 diabetes in which the pancreas can’t 
secrete enough insulin because of which glucose builds up in the blood and the body cannot 
make efficient use of its main source of fuel. This form of diabetes is associated with obesity, 
older age, a family history of diabetes, a history of gestational diabetes, certain medications, 
impaired glucose metabolism, psychological factors, and physical inactivity. Type 2 diabetes 
can be controlled with exercise, diet and lifestyle modifications.[6] This type of diabetes may 
develop microvascular complications, which may lead to retinopathy, nephropathy and 
peripheral and autonomic nephropathies, and macrovascular complications include 
atherosclerotic coronary and peripheral arterial disease.  
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2.1.3 Gestational diabetes 
This type of diabetes develops just before or during the pregnancy. Though the patient may 
have diabetes before the onset of the pregnancy, it is termed gestational only if it is first 
identified after the pregnancy has occurred. Gestational diabetes is caused by the hormones 
of pregnancy which is produced when the placenta supports the growing fetus. These 
hormones may interfere with the mother’s ability to produce and use her own insulin. 
Usually this form of diabetes goes away after the delivery but women who have had 
gestational diabetes have a 20 to 50 percent chance of developing type 2 diabetes within 5 to 
10 years especially those who require insulin during pregnancy and those who are 
overweight. Untreated Gestational Diabetes Mellitus (GDM) can lead to fetal macrosomia, 
hypoglycemia, hypocalcemia and hyperbilirubinemia. Also chances of cesarean delivery 
and chronic hypertension increases in women with GDM. 
2.2 History and causes of diabetes 
Diabetes is not a newly born disease, it has been with human race from long back but, we 
came to knew about it in 1552 B.C. Since after than, many of Greek as well French 
physicians had worked on it and threw some light on the nature of disease, organs 
responsible for it etc. Diabetes was recognized and categorized with complete details and its 
types, Type 1and Type 2 in 1959. In 1870s, a French physician had discovered a link between 
Diabetes and diet intake, and then diabetic diet was formulated with inclusion of milk, oats 
and other fiber containing foods in 1900-1915. Dr. Frederick Banting, Prof. Macleod and Dr. 
Collip discovered the function of insulin, its nature, along with its use started at the 
University of Toronto from 1920 -1923, who were awarded a Noble prize. In 1922, 14 year 
old Leonard Thompson becomes the first human to receive insulin. In the decade of 1940, it 
has been discovered that different organs like kidney and skin are also affected if diabetes is 
creeping from a long term. A major turn in this research was in 1955, when the oral 
hypogycemic drugs had been manufactured. Paul E. Lacy, a JDRF – funded researcher at 
Washington University School of Medicine performs the first successful islets 
transplantation in diabetic animal models in 1976. The first experimental insulin pump was 
developed in 1979 which leads to further refined pumps to provide the infusion of insulin in 
a way which closely mimics the glucose response of human islets. Since then, scientists are 
trying their best to produce results with the most impact. 
Diabetes and its complications occur among Americans of all ages and ethnicities but the 
elderly and certain racial/ethnic groups are more commonly affected. In comparison of non 
– Hispanic whites, African Americans and Hispanics/Latino Americans are about two times 
more likely to be affected by the disease. It has been found that one tribe in Arizona has the 
highest rate of diabetes in the world, with about 50 percent of the adults between the ages of 
30 and 64 with the disease. Population of type 2 diabetes sufferers has officially reached 
epidemic proportions.  
Diabetes mellitus is developed when pancreatic tissue responsible for the production of 
insulin is absent because it is destroyed by disease such as chronic pancreatitis, trauma or 
surgical removal of pancreas. It can also result from other hormonal disturbances such as 
excessive growth hormone production (acromegaly, in which a pituitary gland tumor at the 
base of the brain causes excessive production of growth hormone leading to hyperglycemia) 
and Cushing’s syndrome, in which the adrenal glands produce an excess of cortisol which 
promotes blood sugar elevation. Several other factors that make it more likely that a person 
develop diabetes are as follows: 
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 Age-older than 45 years 
 Obesity 
 Family history of diabetes in a first degree relative (parent or sibling) 
 History with gestational diabetes mellitus 
 Hispanic, Native American, African American, Asian American or Pacific Islander 
descent 
 Hypertension (>140/90 mm Hg) or dyslipidemia (high-density lipoprotein HDL 
cholesterol <35mg/dl or triglyceride level >250mg/dl) 
2.3 Symptoms and diagnosis of diabetes mellitus 
Diabetes mellitus (DM) has diverse intial presentations. The early symptoms of diabetes are 
related to elevated blood sugar levels in the body and loss of glucose in the urine. It usually 
presents with symptomatic hyperglycemia. Common sign and symptoms may include any 
of the following: 
 Being very thirsty 
 Urinating often 
 Feeling very hungry or tired 
 Losing weight without trying 
 Repeated or slow healing infections 
 Having dry, itchy skin 
 Extreme fatigue 
 Blurred vision  
 Tingling or loss of feeling in the hands or feet 
2.4 Biological terms commonly used in diabetes 
Insulin: An anabolic hormone, produced by the beta cells of the islets of Langerhans of 
pancreas in response of elevated blood sugar level in the body. It helps to control the blood 
sugar level in the desirable range. 
Glucose: Glucose is a simple sugar present in everyone’s body. It is an essential nutrient 
that provides energy for the proper functioning of the body cells. After meals, food is 
digested in the stomach and intestines. The glucose in digested food is absorbed by the 
intestinal cells into the blood stream and is carried by the blood to all the cells in the body. 
Glucose needs insulin to enter into the body as it can not get into the cells alone. 
Glucagon: Glucagon is a hormone synthesized and secreted from alpha cells of the 
pancreatic islets used for carbohydrate metabolism. Its secretion increases rapidly when the 
sugar level is too low in the body. It maintains the level of glucose in the blood by binding to 
specific receptors on hepatocytes causing the liver to release its intracellular stores of 
glucose. As these stores become depleted, glucagon then encourages the liver to synthesize 
glucose by gluconeogenesis which will be released to prevent the development of 
hypoglycemia, low sugar level.  
Insulin Resistance: Sometimes the cells throughout the body become resistant to the insulin 
produced by the pancreas due to which it becomes difficult for the sugar to enter the cells. 
This condition is known as insulin resistance. 
Diabetic Ketoacidosis: It is a condition in which the cells of muscle, liver and other body 
parts are unable to take up glucose for producing energy due to the absence of insulin. It is a 
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state of absolute or relative insulin deficiency aggravated by hyperglycemia, dehydration, 
and acidosis-producing derangements in intermediary metabolism. To avoid starvation the 
body begins to break down fat for energy. Fatty acids and ketone bodies are released due to 
the break down of fat causing chemical imbalance (metabolic imbalance) called Diabetic 
Ketoacidosis. Moderate or large amounts of ketones in urine are dangerous. They upset the 
chemical balance of the blood.  
Chronic hyperglycemia: Chronic hyperglycemia means elevated blood sugar level in the 
blood.  
2.5 Treatment therapies for diabetes 
Type 1 Diabetes is very serious, with a sudden and dramatic onset, usually in youth. Type 1 
diabetes is an autoimmune condition, where the body attacks its own insulin producing 
cells. The body’s immune cells, or white blood cells, include B cells and T cells. B cells make 
antibodies and present ‘antigens’ to T cells, allowing them to recognize, and kill invaders. 
People with Type 1 diabetes must maintain an insulin-monitoring and insulin-injecting 
regimen for the rest of their lives as the islets of Langerhans are destroyed in this type of 
diabetes. Treatment for type 1 diabetes includes taking insulin shots or insulin pump to 
deliver insulin in the body, making wise food choices, exercising regularly and controlling 
blood pressure and cholesterol.  
Type 2 diabetes can be treated successfully with diet, physical activity and medication, if 
necessary.[23] Physical activity can help to control blood sugar levels and increases body’s 
sensitivity to insulin.[6] Also, it helps delays or stop heart diseases, a leading complication 
of diabetes. Diet plays an extremely important role in controlling this type of diabetes. Being 
overweight can increase the chances of developing type 2 diabetes. Usually GDM in 
pregnant women disappears itself after delivery. 
2.6 Mathematical model 
The first approach to measure the insulin sensitivity in vivo was introduced by Himsworth 
and Ker [24] and the first mathematical model to estimate the glucose disappearance and 
insulin sensitivity was proposed by Bolie. In this model, he assumed that glucose 
disappearance is a linear function of both glucose and insulin. The insulin secretion and 
disappearance is proportional to glucose and plasma insulin concentration respectively. 
The main objective here is to prescribe a more accurate, but less simple, method of arranging 
the palatable composition of a diabetic diet. 
The modified coupled differential equations for the plasma glucose and insulin 
concentration [1-14, 16-22], when the normal fasting level of plasma glucose is 70 - 120 
mg/dl, are given as follows 
      1 2 0 0 3dg l hg l g g U g g l F t
dt
       (1) 
      4 0 0 5 0 6dh l g g U g g l h l I t
dt
      (2) 
where, g(t) - plasma glucose concentration, h(t) - insulin concentration, li - sensitivity 
constants, i = 1,2,3,4,5,6, F(t) - food source input for plasma glucose, I(t) – insulin input and 
U(g0 - g) is unit step function.  
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The insulin input I(t) will be given through injection at subcutaneous  level at periodic 
intervals, which leaks its contents into the system over a period of time. Therefore, I(t) may 









At t = t0, I(t) = 0 
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   ,   - quantity of injection, t0 – time of injection, t  -time lag to 
maximum. 
Food input source term, F(t), is the source for food input to the plasma glucose level, the 
contents of which are reduced in a simple exponential manner. Therefore, F(t) may be 
modeled as 
 








         (4) 
where, S - quantity constant of meal,  - delay parameter. 
For 0 ,t t in non – diabetic case, ( ) 0F t   and ( ) 0I t  and for diabetic case, ( ) 0F t  , ( ) 0I t  . 
A mathematical model for the dynamics of glucose concentration in patients with type 1 
diabetes using CSII [15] therapy as an external source of insulin has been developed by us. 
We attempt to model the effect of an external source of insulin release, as a prescribed 
function of time, on glucose levels. The model is then used to assess the optimal insulin 
release profile, and the threshold amount required to bring the level of glucose to within a 
normal physiological range. 
To model the pump’s delivery of insulin, we take into account three major factors: (i) the 
total amount of insulin released over a specific period; (ii) the time profile of insulin release, 
f(t); and (iii) the glucose threshold concentration Gc, below which the pump stops releasing 
insulin. The amount of insulin (TDD) is proportional to the total amount of glucose, whose 
concentration is assessed by the sensor in the pump’s controller. This amount is released by 
the pump in a dual wave shaped insulin bolus which allows the patient to combine both 
normal and square wave techniques. The body characteristics of the patient determine how 
much insulin is needed to maintain the glucose level within the normal physiological range 
after each meal. The dual wave shape also provides a rapid increase in insulin plasma 
concentration, and sustained high circulating insulin levels while a meal is being consumed. 
Here, we extend the minimal model to incorporate the above factors, which leads to the 
following differential equations: 
         1( ) ,b
dG
X G l G G
dt
          (5) 
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 1 2( ),b
dX
p X p I I
dt
     (6) 
 2 3( ) ( ) ( ),c b
dI
l G G f t l I I
dt
      (7) 
where G is the blood glucose concentration, X is an auxiliary function representing remote 
insulin action, and l is the insulin plasma concentration. A description of the model 
parameters and their values are given in Table 1. 
The important part of this extension is the first term of (7) which models all three factors 
mentioned above. This term contributes to the insulin plasma when the glucose 
concentration exceeds the threshold Gc, and is defined as 
 22






l G t G f t if G t G
l G G
if G t G
    
 (8) 
The function models the profile of insulin release from the pump, and the coefficient 
represents a scaling factor determining TDD of insulin released by the pump. In the next 
section, we discuss different profiles of insulin release and compare their effects on the 
optimal control of glucose concentration. The newer generation of pumps can be 
programmed to release insulin using three different bolus techniques.  
A normal bolus can be used if small amounts of carbohydrates are consumed or if a 
correction to the blood glucose level outside the physiological range needs to be made. A 
square wave profile is helpful when eating foods that are high in both fat/protein and 
carbohydrate (fat and protein delay the absorption of carbohydrates). If a normal bolus is 
given for a meal high in protein and fat concentrations, circulating insulin levels rise rapidly 
and may peak before the carbohydrates are absorbed. This mismatch in insulin and blood 
glucose levels can result in postprandial hypoglycemia. Therefore, a dual wave bolus, as a 
combination of the normal and square wave bolus techniques, can be introduced. Using this 
technique, half of the insulin dose is given (over a short period of time) at the onset of the 
meal, and the remainder over a 2–4 h period. The profile of a dual wave bolus is modeled as 
a function of time, f(t), in Eq. (4) over a period of 3 h (Fig. 1(a)–(c)).  
 
 
Fig. 1. Profile of insulin release by the pump f(t), for 3h: HLL release; (b)LHL release; (c) 
LLH release, where H stands for high amount release of insulin and L stands for its low 
amount per hour f(t) is normalized so that H=L 
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S No Parameter Description Value Unit 
1 Gb 
Base line value of glucose concentration in 
plasma 
118 mg dl-1 
2 Gc Glucose threshold concentration in plasma 100-107 mg dl-1 
3 Ib 
Baseline value of insulin concentration in 
plasma 
7 µU ml-1 
4 l1 
The insulin dependent rate of tissue glucose 
uptake 
10 Min-1 
5 l2 Scaling factor determining TDD of insulin Variable min-1 µU mg-1 
6 l3`` The rate of decay for insulin in plasma 0.264 min-1 
7 p1 




The rate of insulin – dependent increase in 
tissue glucose uptake due to  insulin 
concentration excess over its baseline 
0.007 min-2 µU ml-1 
Table 1. Description and values of the model parameters obtained from the published 
literature 
This particular work is published in Applied Mathematics and computation, 2007, pages 
1476 – 1483 and has been cited by Kato, R, Munkhjargal, M and Takahashi, D “An 
autonomous drug release system based on chemo- mechanical energy conversion “Organic 
Engine” for feedback control of blood glucose”, Biosensors and Bioelecetronics in 2010 Vol 
26(4), pages 1455 - 1459. 
2.7 Future work 
More advanced mathematical models can be formulated to explain the effects of obesity on 
diabetes, effects of exercise on management of type 2 diabetes. Parameters involving glucose 
sensors can be added to the insulin pump model for a better programmed insulin delivery 
by insulin pump. 
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This book is intended as an overview of recent progress in type 1 diabetes research worldwide, with a focus on
different research areas relevant to this disease. These include: diabetes mellitus and complications,
psychological aspects of diabetes, perspectives of diabetes pathogenesis, identification and monitoring of
diabetes mellitus, and alternative treatments for diabetes. In preparing this book, leading investigators from
several countries in these five different categories were invited to contribute a chapter to this book. We have
striven for a coherent presentation of concepts based on experiments and observation from the authors own
research and from existing published reports. Therefore, the materials presented in this book are expected to
be up to date in each research area. While there is no doubt that this book may have omitted some important
findings in diabetes field, we hope the information included in this book will be useful for both basic science
and clinical investigators. We also hope that diabetes patients and their family will benefit from reading the
chapters in this book.
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